As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > COMMENTARY
COMMENTARY
-
2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
-
LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
-
After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
-
Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?
November 27, 2018
-
There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
-
Astellas/Daiichi Sankyo Showdown Looms as Their FLT3 Inhibitors Near Approval
July 12, 2018
-
LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications
July 5, 2018
-
Kudos to MHLW for Creating New Confab, but 1st Meeting Stirs Industry Frustration
May 30, 2018
-
Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts
April 23, 2018
-
With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions
April 4, 2018
-
Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?
March 12, 2018
-
With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
-
Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
January 15, 2018
-
Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
-
Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
-
With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
-
Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
-
MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
-
Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
-
Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…